Rachel Pope, MD
Gynecology · Cleveland, OHNPI 1255623658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,497 of the $48,648 with a category attached, or 64.7%. Astellas Pharma US Inc accounts for 67.6% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $27,605, more than ten times the $2,546 reported in 2021. Among gynecology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $383.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$33K
- Medical Device Business Services, Inc.$10K
- Bayer$2K
- Synthes USA Products LLC$1K
- Kerecis Limited$434
- Merck$215
- plus $2K from 23 others
What the payments were for
- Consulting fees$9,92020%
- Speaking & faculty fees$31,49765%
- Travel & lodging$3,7428%
- Food & beverage$3,3267%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 42 | $32,887 |
| Medical Device Business Services, Inc. | 20 | $9,870 |
| Bayer | 1 | $2,454 |
| Synthes USA Products LLC | 5 | $1,169 |
| Kerecis Limited | 4 | $434 |
| Merck | 9 | $215 |
| Axonics, Inc. | 3 | $173 |
| Integra Lifesciences Corporation | 2 | $152 |
| Mayne Pharma Commercial LLC | 2 | $150 |
| Coloplast | 1 | $138 |
| Biotissue Holdings Inc. | 1 | $124 |
| AbbVie(2 entities) | 6 | $114 |
| Sumitomo Pharma America, Inc. | 6 | $96 |
| Caldera Medical, Inc | 1 | $84 |
| Dentsply IH AB | 4 | $84 |
| Johnson & Johnson | 5 | $80 |
| Scynexis, Inc. | 1 | $75 |
| Applied Medical Resources Corporation | 1 | $66 |
| Aroa Biosurgery Incorporated | 2 | $41 |
| Photocure Inc | 2 | $35 |
| Immunitybio, Inc. | 1 | $35 |
| Teleflex LLC | 1 | $26 |
| Millicent US Inc | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$32,400
- NA$9,870
- Lynkuet$2,454
- Kerecis SurgiClose$1,243
- Kerecis Omega3 Marigen$440
- Kerecis GraftGuide$311
- TITAN$138
- Bulkamid$125
- NEOX$124
- CLARIX$124
- Kerecis Omega3 SurgiClose$110
How this compares
$48,648 in reported general payments places this provider in the 95th percentile of 77 gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 85 | $51,412 |
| MyrbetriqMirabegron | 57 | $36,228 |
| Estradiol | 119 | $6,894 |
| VeozahFezolinetant | 14 | $6,850 |
| Trospium Chloride | 31 | $2,501 |
| Clobetasol Propionate | 51 | $2,354 |
| Testosterone | 11 | $2,087 |
| YuvafemEstradiol | 14 | $1,801 |
| ProgesteroneProgesterone, Micronized | 27 | $1,392 |
| ValacyclovirValacyclovir Hcl | 11 | $631 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 46 | $630 |
| Pregabalin | 11 | $215 |
| Ciprofloxacin Hcl | 15 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $96 | $51,41285 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $32,887 | $43,07871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 gynecology providers in Ohio.
Other gynecology in Cleveland
- Megan BillowCleveland$83K
- Rosanne Marie KhoCleveland$19K
- Paula EscobarCleveland$5K
- Yolando McGriff ChatmanCleveland$728
- Stephanie ThomasCleveland$477
- Youssef YoussefCleveland$197
- Derek VanamerongenCincinnati$316K
- Joseph FranzeseCincinnati$18K
- Susan Clark-FrantzNorton$10K
- Amber Bondurant SullivanGahanna$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.